Rakuten’s CEO raises $150M to fund his biotech outfit Aspyrian’s cancer photoimmunotherapies | FierceBiotech
Aug 24, 2018 @ 12:10

Rakuten Aspyrian has raised $150 million in a series C round to fund its photoimmunotherapy platform and a phase 3 trial in head and neck cancer, alongside plans to expand its pipeline to include other tumor types, both as a monotherapy and in combination with other cancer treatments.

Sourced through Scoop.it from: www.fiercebiotech.com

Leave a Reply